Descending
|
12/19/2007 Michael J. Fox Foundation Awards $2 Million To Continue Search For Biomarkers of Parkinson's Disease
Funding initiative is dedicated to developing objective biomarkers, or “biological fingerprints,” of Parkinson’s disease.
12/18/2007 Michael J. Fox Foundation Awards $4.4 Million for Development of New Class of Parkinson's Therapy
Project targets glutamate receptor mGluR4 for symptomatic treatment that could replace levodopa, transforming treatment of PD
12/14/2007 Katie Hood Appointed Chief Executive Officer of The Michael J. Fox Foundation
Key architect of Foundation’s strategy will build on and expand transformational approach.
12/13/2007 MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
The Michael J. Fox Foundation for Parkinson's Research has committed up to $2 million for research toward therapies to alleviate Parkinson's-related cognitive dysfunction and mood disorders. The funding is to be awarded under a new initiative, Cognitive Deficits and Mood Disorders in Parkinson's Disease, made possible by generous leadership funding from Merck Serono (EMD Serono in North America), affiliates of Merck KGaA, Darmstadt, Germany.
12/12/2007 MJFF Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
Having funded $2 million total to support 27 high-risk, high-reward approaches to Parkinson’s disease research in the first year of its Rapid Response Innovation Awards (RRIA) initiative, The Michael J. Fox Foundation announced that it will commit $2 million to a second round of funding in 2008.
12/04/2007 Five Clinical Studies to Receive $2.5 Million
The Michael J. Fox Foundation for Parkinson’s Research today announced approximately $2.5 million in total funding for five clinical research studies under its 2007 Clinical Discovery Program. In keeping with the Foundation’s focus on accelerating scientific solutions that can have a tangible effect on patients’ lives, this annual initiative funds clinical research projects with strong potential to yield new treatments for people living with PD.
11/29/2007 Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
In keeping with The Michael J. Fox Foundation’s mission to accelerate scientific breakthroughs that can transform the lives of people with Parkinson’s disease, the Foundation today announced the appointment of Irene Hegeman Richard, MD, to the newly created role of Senior Medical Advisor.
11/01/2007 Michael J. Fox Foundation Commits up to $2 Million for PD Drug Development under Target Validation 2008
The Foundation announced the launch of its 2008 Target Validation effort. Under this annual program MJFF will award up to $2 million in 2008 for projects designed to validate the therapeutic potential of scientific discoveries, pushing them one step closer to possible pharmaceutical industry investment and clinical trials.
10/01/2007 Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
Former research team director and key strategy architect to build on Foundation’s momentum in pursuing systemic changes to advance Parkinson’s disease treatments
08/21/2007 MJFF and New York Academy of Sciences to Host First Major Parkinson's Drug Development Conference
The Michael J. Fox Foundation for Parkinson’s Research and The New York Academy of Sciences will co-host the first and only major scientific symposium exclusively focused on the development of innovative drugs to target Parkinson’s disease.
08/01/2007 MJFF Announces $1.2 Million in Funding to Advance Development of Drug Targets for PD
The Michael J. Fox Foundation for Parkinson’s Research announced $1.2 million in total awards to four research teams working to advance potentially disease-modifying therapeutic targets for PD along the drug development pipeline. The funding was awarded under the Novel Approaches to Drug Discovery for Parkinson’s Disease program, made possible by generous leadership funding from Elan Corporation, plc (NYSE: ELN), a neuroscience-based biotechnology company.
07/11/2007 MJFF Awards $2 Million to Advance Nine Potential Drug Targets for Parkinson's Disease
The Michael J. Fox Foundation for Parkinson’s Research has awarded $2 million total to nine research teams working to validate therapeutic targets for Parkinson’s disease. The awards were made under MJFF’s annual Target Validation initiative, which is designed to accelerate the rate at which new Parkinson’s therapies are brought to market.
06/06/2007 MJFF Awards $710,000 to Advance Understanding of Parkinson's Disease Subtypes
The Michael J. Fox Foundation for Parkinson’s Research announced $710,000 in total funding to seven research teams for projects to initially characterize Parkinson’s disease subtypes — distinct forms of the disease that may differ in onset, progression and response to treatment.
06/05/2007 Foundation Commits Up To $5 Million For 2007-2008 Therapeutics Development Initiative
MJFF announced the launch of its 2007-2008 Therapeutics Development Initiative, designed to promote industry investment in preclinical research for Parkinson’s disease.
05/24/2007 Foundation Commits Up to $2 Million to Address 'Critical Challenges' in Parkinson's Disease
MJFF announced the launch of Critical Challenges in PD, designed to address highly specific questions whose answers are critical to accelerating the development of improved treatments for Parkinson’s disease.
05/24/2007 MJFF Announces New Conference Call Q&A Sessions for Researchers
The Michael J. Fox Foundation has announced that, going forward, it will host a conference call question-and-answer session on every funding initiative it launches. The calls will allow researchers to speak directly with Research Programs staff on the specific goals of a program of interest, as well as the types of proposals appropriate for the program.
05/23/2007 MJFF Awards $1 Million For Critical Next Steps On Projects Initiated Under Community Fast Track 2005
The Foundation announced that it has awarded $1 million in supplemental funding to five investigators to push forward promising results of work funded under the Foundation’s Community Fast Track 2005 program.
05/03/2007 Michael J. Fox BIO Keynote to Urge Bolder Moves in Translational Research
04/05/2007 Foundation Continues to Lead Search for Biomarkers of Parkinson's Disease
The Michael J. Fox Foundation announced the launch of Biomarkers 2007, a two-year, $2-million funding program dedicated to research toward the discovery of an objective biomarker, or "biological fingerprint," of Parkinson’s disease.
03/29/2007 Michael J. Fox Foundation Commits Up to $3 Million for High-Impact Clinical Research
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced the launch of its 2007 Clinical Discovery Program.
03/01/2007 Foundation Announces Changes in Leadership, New CEO
Sarah Orsay named Chief Executive Officer; Founding CEO Deborah W. Brooks to remain as President and Co-Founder
01/23/2007 Foundation Awards $4.6 Million to 10 Industry Teams for Parkinson's Drug Development Research
The Therapeutics Development Initiative is a key element in MJFF's strategy to ‘de-risk’ preclinical Parkinson’s disease research for biotech and pharmaceutical companies, thus expanding and catalyzing industry investments in the development of improved PD treatments and a cure.
01/04/2007 Foundation Launches Rapid Response Innovation Awards
"Just in time" funding for high-risk, high-reward approaches to PD
